I. Objective and necessity
- Idiopathic pulmonary fibrosis (IPF) is a fatal disease which could become fibrosis and 80 % of the people who get a diagnosis generally die within 5 years. Currently the standard therapy and effective treatment has been d...
I. Objective and necessity
- Idiopathic pulmonary fibrosis (IPF) is a fatal disease which could become fibrosis and 80 % of the people who get a diagnosis generally die within 5 years. Currently the standard therapy and effective treatment has been developed yet
- Many drugs have been tried for the treatment of IPF. However it is difficult for the effect of the treatment and safety to be proved. Improved drug development is seriously needed
II. Content and scope
- The efficacy test and selection of final candidate in IPF model
- The mechanism test for IPF
- Formulationa and analysis test of final cadidate
- The performance of nonclinical study for IND submission
- The sample preparation and stability test for phase I trial
- The preparation of document and approval for phase I trial
III. Results
- The completion of bleomycin and PHMG induced IPF model for 5 candidates
- The completion of EMT, inflammatory inhibition, OCR for 5 candidates
- The completion of analysis test for drug substance in final candidate (HL156271)
- Nonclinical toxicity studies for IND as oral has been completed, the inhalation toxicity study in progress
- After inhalation toxicity study is finished, Phase I trial wll be performed
IV. The application plan
- The final candidate is considered to be able to take advantage of an excellent standard therapy